125 related articles for article (PubMed ID: 16846233)
1. Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate.
Fu Z; Chen S; Baldwin MR; Boldt GE; Crawford A; Janda KD; Barbieri JT; Kim JJ
Biochemistry; 2006 Jul; 45(29):8903-11. PubMed ID: 16846233
[TBL] [Abstract][Full Text] [Related]
2. Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex.
Silvaggi NR; Wilson D; Tzipori S; Allen KN
Biochemistry; 2008 May; 47(21):5736-45. PubMed ID: 18457419
[TBL] [Abstract][Full Text] [Related]
3. The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability.
Baldwin MR; Bradshaw M; Johnson EA; Barbieri JT
Protein Expr Purif; 2004 Sep; 37(1):187-95. PubMed ID: 15294297
[TBL] [Abstract][Full Text] [Related]
4. Structure of botulinum neurotoxin type D light chain at 1.65 A resolution: repercussions for VAMP-2 substrate specificity.
Arndt JW; Chai Q; Christian T; Stevens RC
Biochemistry; 2006 Mar; 45(10):3255-62. PubMed ID: 16519520
[TBL] [Abstract][Full Text] [Related]
5. Quinolinol and peptide inhibitors of zinc protease in botulinum neurotoxin A: effects of zinc ion and peptides on inhibition.
Lai H; Feng M; Roxas-Duncan V; Dakshanamurthy S; Smith LA; Yang DC
Arch Biochem Biophys; 2009 Nov; 491(1-2):75-84. PubMed ID: 19772855
[TBL] [Abstract][Full Text] [Related]
6. A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease.
Burnett JC; Opsenica D; Sriraghavan K; Panchal RG; Ruthel G; Hermone AR; Nguyen TL; Kenny TA; Lane DJ; McGrath CF; Schmidt JJ; Vennerstrom JL; Gussio R; Solaja BA; Bavari S
J Med Chem; 2007 May; 50(9):2127-36. PubMed ID: 17417831
[TBL] [Abstract][Full Text] [Related]
7. Substrate recognition strategy for botulinum neurotoxin serotype A.
Breidenbach MA; Brunger AT
Nature; 2004 Dec; 432(7019):925-9. PubMed ID: 15592454
[TBL] [Abstract][Full Text] [Related]
8. Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A.
Ho M; Goh CH; Brothers MC; Wang S; Young RL; Ou Y; Lui JN; Kalafatis M; Lan X; Wolf AE; Rienstra CM; Wilson BA
Protein Sci; 2012 Mar; 21(3):318-26. PubMed ID: 22170566
[TBL] [Abstract][Full Text] [Related]
9. Modulation of botulinum neurotoxin A catalytic domain stability by tyrosine phosphorylation.
Ibañez C; Blanes-Mira C; Fernández-Ballester G; Planells-Cases R; Ferrer-Montiel A
FEBS Lett; 2004 Dec; 578(1-2):121-7. PubMed ID: 15581628
[TBL] [Abstract][Full Text] [Related]
10. Multiple pocket recognition of SNAP25 by botulinum neurotoxin serotype E.
Chen S; Barbieri JT
J Biol Chem; 2007 Aug; 282(35):25540-7. PubMed ID: 17609207
[TBL] [Abstract][Full Text] [Related]
11. Structural analysis of botulinum neurotoxin serotype F light chain: implications on substrate binding and inhibitor design.
Agarwal R; Binz T; Swaminathan S
Biochemistry; 2005 Sep; 44(35):11758-65. PubMed ID: 16128577
[TBL] [Abstract][Full Text] [Related]
12. Peptide inhibitors of botulinum neurotoxin by mRNA display.
Yiadom KP; Muhie S; Yang DC
Biochem Biophys Res Commun; 2005 Oct; 335(4):1247-53. PubMed ID: 16122707
[TBL] [Abstract][Full Text] [Related]
13. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4.
Arndt JW; Jacobson MJ; Abola EE; Forsyth CM; Tepp WH; Marks JD; Johnson EA; Stevens RC
J Mol Biol; 2006 Sep; 362(4):733-42. PubMed ID: 16938310
[TBL] [Abstract][Full Text] [Related]
14. Cloning, expression, and purification of C-terminal quarter of the heavy chain of botulinum neurotoxin type A.
Sharma S; Zhou Y; Singh BR
Protein Expr Purif; 2006 Feb; 45(2):288-95. PubMed ID: 16143544
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of botulinum neurotoxin type A and implications for toxicity.
Lacy DB; Tepp W; Cohen AC; DasGupta BR; Stevens RC
Nat Struct Biol; 1998 Oct; 5(10):898-902. PubMed ID: 9783750
[TBL] [Abstract][Full Text] [Related]
16. Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility.
Silvaggi NR; Boldt GE; Hixon MS; Kennedy JP; Tzipori S; Janda KD; Allen KN
Chem Biol; 2007 May; 14(5):533-42. PubMed ID: 17524984
[TBL] [Abstract][Full Text] [Related]
17. Botulinum neurotoxin serotype F: identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity.
Schmidt JJ; Stafford RG
Biochemistry; 2005 Mar; 44(10):4067-73. PubMed ID: 15751983
[TBL] [Abstract][Full Text] [Related]
18. Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A.
Park JG; Sill PC; Makiyi EF; Garcia-Sosa AT; Millard CB; Schmidt JJ; Pang YP
Bioorg Med Chem; 2006 Jan; 14(2):395-408. PubMed ID: 16203152
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A.
Masuyer G; Thiyagarajan N; James PL; Marks PM; Chaddock JA; Acharya KR
Biochem Biophys Res Commun; 2009 Mar; 381(1):50-3. PubMed ID: 19351593
[TBL] [Abstract][Full Text] [Related]
20. Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding.
Burnett JC; Schmidt JJ; McGrath CF; Nguyen TL; Hermone AR; Panchal RG; Vennerstrom JL; Kodukula K; Zaharevitz DW; Gussio R; Bavari S
Bioorg Med Chem; 2005 Jan; 13(2):333-41. PubMed ID: 15598556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
